Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Mol Cancer Ther
; 21(2): 322-335, 2022 02.
Article
in En
| MEDLINE
| ID: mdl-34789563
Full text:
1
Database:
MEDLINE
Main subject:
Drug Resistance, Neoplasm
/
Protein Kinase Inhibitors
/
High-Throughput Nucleotide Sequencing
/
Molecular Docking Simulation
Limits:
Animals
/
Female
/
Humans
Language:
En
Year:
2022
Type:
Article